Erasca Narrows Q2 Loss by 46% Amid R&D Cost Cuts

TL;DR

**Erasca is burning less cash and narrowing losses, but still years away from revenue, making it a high-risk bet on pipeline success.**

AI Summary

Erasca, Inc. reported a net loss of $33.876 million for the three months ended June 30, 2025, a significant improvement from the $63.201 million net loss in the same period of 2024, representing a 46.39% reduction. For the six months ended June 30, 2025, the net loss was $64.842 million, down from $98.218 million in 2024, a 34.09% decrease. Research and development expenses decreased substantially to $21.170 million for the three months ended June 30, 2025, from $33.032 million in 2024, and to $47.139 million for the six months ended June 30, 2025, from $61.606 million in 2024. The company's total assets decreased from $502.526 million as of December 31, 2024, to $445.386 million as of June 30, 2025. Cash, cash equivalents, and marketable securities totaled $386.7 million as of June 30, 2025, which the company believes is sufficient to fund operations for at least one year. The accumulated deficit grew to $832.505 million by June 30, 2025, from $767.663 million at December 31, 2024. The company continues to finance its operations through equity offerings and does not expect product sales revenue for several years.

Why It Matters

Erasca's significant reduction in net loss and R&D expenses signals a potential shift towards greater financial discipline, which could be a positive for investors concerned about burn rate in a competitive oncology space. While the company still faces a substantial accumulated deficit, the extended cash runway of at least one year provides crucial time for its RAS/MAPK pathway-focused pipeline to advance. This financial management could enhance investor confidence, allowing Erasca to better compete with larger pharmaceutical companies in the precision oncology market and potentially attract future collaborations, ultimately impacting the availability of new cancer therapies for patients.

Risk Assessment

Risk Level: high — Erasca has an accumulated deficit of $832.505 million as of June 30, 2025, and does not expect to generate product sales revenue for at least the next several years, if ever. The company relies entirely on external financing, and its failure to secure additional capital or partnerships would negatively impact its financial condition and could force it to delay or terminate research and development programs.

Analyst Insight

Investors should closely monitor Erasca's clinical trial progress and future financing activities. Given the high-risk profile and reliance on future capital, consider this a speculative investment and allocate only a small portion of a diversified portfolio, focusing on long-term potential rather than short-term gains.

Financial Highlights

debt To Equity

0.20

revenue

$0

operating Margin

N/A

total Assets

$445.386M

total Debt

$73.128M

net Income

-$33.876M

eps

-$0.12

gross Margin

N/A

cash Position

$386.7M

revenue Growth

N/A

Key Numbers

• $33.876M — Net Loss (Q2 2025) (46.39% decrease from $63.201M in Q2 2024)
• $64.842M — Net Loss (YTD Q2 2025) (34.09% decrease from $98.218M in YTD Q2 2024)
• $21.170M — Research and Development Expenses (Q2 2025) (Decreased from $33.032M in Q2 2024)
• $47.139M — Research and Development Expenses (YTD Q2 2025) (Decreased from $61.606M in YTD Q2 2024)
• $386.7M — Cash, Cash Equivalents and Marketable Securities (As of June 30, 2025, sufficient to fund operations for at least one year)
• $832.505M — Accumulated Deficit (As of June 30, 2025, increased from $767.663M at Dec 31, 2024)
• $445.386M — Total Assets (As of June 30, 2025, decreased from $502.526M at Dec 31, 2024)
• 283,670,139 — Common Stock Outstanding (As of August 5, 2025)

Key Players & Entities

• Erasca, Inc. (company) — clinical-stage precision oncology company
• Asana BioSciences, LLC (company) — merged with Erasca in November 2020
• ASN Product Development, Inc. (company) — became Erasca's wholly-owned subsidiary
• Erasca Australia Pty Ltd (company) — wholly-owned Australian subsidiary
• Erasca Ventures, LLC (company) — wholly-owned subsidiary for equity investments
• SEC (regulator) — Securities and Exchange Commission
• FASB (regulator) — Financial Accounting Standards Board
• Nasdaq Global Select Market (company) — exchange where ERAS common stock is registered

FAQ

Risk Factors

• Continued Net Losses and Accumulated Deficit [high — financial]: Erasca reported a net loss of $33.876 million for Q2 2025 and $64.842 million for the first six months of 2025. The accumulated deficit has grown to $832.505 million as of June 30, 2025. The company has no product sales revenue and relies on equity offerings, indicating a significant ongoing need for capital to sustain operations.
• Dependence on Equity Financing [high — financial]: The company continues to finance its operations through equity offerings and does not expect product sales revenue for several years. This reliance exposes Erasca to market conditions for equity capital and potential dilution for existing shareholders.
• Significant Reduction in R&D Spending [medium — operational]: Research and development expenses decreased by 36% to $21.170 million for Q2 2025 and by 23.5% to $47.139 million for the first six months of 2025 compared to the prior year. While this improves near-term losses, it could impact the pace of drug development and future product pipeline.
• Declining Total Assets [medium — financial]: Total assets decreased from $502.526 million at December 31, 2024, to $445.386 million as of June 30, 2025. This reduction, coupled with ongoing losses, suggests a potential contraction in the company's resource base.
• Cash Burn Rate and Runway [medium — financial]: While the company states its $386.7 million cash position as of June 30, 2025, is sufficient for at least one year, the significant net losses and R&D expenses indicate a substantial cash burn rate. Future funding rounds will be critical.

Industry Context

Erasca operates in the biotechnology sector, a highly competitive and capital-intensive industry focused on drug discovery and development. Success hinges on innovation, clinical trial outcomes, and regulatory approvals. The industry faces significant R&D costs, long development timelines, and high failure rates, with companies often relying on substantial external funding.

Regulatory Implications

As a clinical-stage biotechnology company, Erasca is subject to stringent regulations from bodies like the FDA. Delays in clinical trials, failure to meet efficacy or safety standards, or changes in regulatory pathways can significantly impact development timelines and the potential for market approval.

What Investors Should Do

1. Monitor R&D spending trends closely.
2. Evaluate the sustainability of the current cash runway.
3. Assess the impact of the declining asset base.

Key Dates

• 2025-06-30: End of Second Quarter 2025 — Reporting period for the Q2 and YTD financial results, showing reduced net losses and R&D expenses, but also a decrease in total assets and an increase in accumulated deficit.
• 2025-12-31: End of Fiscal Year 2024 — Baseline for comparison of asset and liability changes, and accumulated deficit growth.

Glossary

Accumulated deficit

The cumulative net losses of a company since its inception, minus any cumulative net income. It represents a deficit in retained earnings. (Indicates the company has historically incurred more losses than profits, growing to $832.505 million by June 30, 2025.)

In-process research and development

Costs incurred for research and development projects that have not yet reached technological feasibility and have no alternative future use. (Erasca expensed $7.5 million in Q2 2025 and $7.5 million YTD Q2 2025 for these projects, a significant reduction from prior year periods.)

Marketable securities

Investments in debt or equity securities that can be readily bought or sold in the open market. (A significant portion of Erasca's assets, totaling $320.606 million ($234.518M short-term and $86.088M long-term) as of June 30, 2025, contributing to its cash position.)

Operating lease assets

Assets recognized under accounting standards for leases, representing the right to use an underlying asset for the lease term. (Represents $30.814 million of Erasca's assets as of June 30, 2025, reflecting its use of leased facilities or equipment.)

Year-Over-Year Comparison

Compared to the prior year, Erasca has significantly reduced its net losses, with Q2 2025 losses down 46.39% to $33.876 million and YTD losses down 34.09% to $64.842 million. This improvement is largely driven by a substantial decrease in R&D expenses, down 36% for the quarter and 23.5% year-to-date. However, total assets have declined by approximately 11.4% to $445.386 million, and the accumulated deficit has increased by $64.842 million to $832.505 million, indicating continued operational losses despite cost controls.

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share ERAS Nasdaq Glo

Filing Documents

• eras-20250630.htm (10-Q) — 2463KB
• eras-ex31_1.htm (EX-31.1) — 16KB
• eras-ex31_2.htm (EX-31.2) — 16KB
• eras-ex32_1.htm (EX-32.1) — 9KB
• eras-ex32_2.htm (EX-32.2) — 9KB
• img200537042_0.jpg (GRAPHIC) — 631KB
• 0001193125-25-178996.txt ( ) — 12394KB
• eras-20250630.xsd (EX-101.SCH) — 1321KB
• eras-20250630_htm.xml (XML) — 2344KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024 1 Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2025 and 2024 2 Condensed Consolidated Statements of Stockholders' Equity for the three and six months ended June 30, 2025 and 2024 3 Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 2024 4 Notes to Condensed Consolidated Financial Statements 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 35 Item 4.

Controls and Procedures

Controls and Procedures 35 PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 37 Item 1A.

Risk Factors

Risk Factors 37 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 37 Item 3. Defaults Upon Senior Securities 37 Item 4. Mine Safety Disclosures 37 Item 5. Other Information 37 Item 6. Exhibits 39

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

. Financial Statements

Item 1 . Financial Statements. Erasca, Inc. Condensed Consolidated Balance Sheets (In thousands, except share and par value amounts) (Unaudited) June 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 66,143 $ 67,739 Short-term marketable securities 234,518 230,570 Prepaid expenses and other current assets 9,999 10,484 Total current assets 310,660 308,793 Long-term marketable securities 86,088 142,164 Property and equipment, net 14,825 16,321 Operating lease assets 30,814 32,218 Restricted cash 408 408 Other assets 2,591 2,622 Total assets $ 445,386 $ 502,526 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 1,663 $ 468 Accrued expenses and other current liabilities 21,779 26,308 Operating lease liabilities 4,709 4,619 Total current liabilities 28,151 31,395 Operating lease liabilities, net of current portion 44,714 47,270 Other liabilities 263 362 Total liabilities 73,128 79,027 Commitments and contingencies (Note 12) Stockholders' equity: Preferred stock, $ 0.0001 par value; 80,000,000 shares authorized at June 30, 2025 and December 31, 2024; no shares issued and outstanding at June 30, 2025 and December 31, 2024 — — Common stock, $ 0.0001 par value; 800,000,000 shares authorized at June 30, 2025 and December 31, 2024; 283,650,139 and 283,218,344 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 28 28 Additional paid-in capital 1,204,320 1,190,729 Accumulated other comprehensive income 415 405 Accumulated deficit ( 832,505 ) ( 767,663 ) Total stockholders' equity 372,258 423,499 Total liabilities and stockholders' equity $ 445,386 $ 502,526 The accompanying notes are an integral part of these condensed consolidated financial statements. 1 Erasca, Inc. Condensed Consolidated Statemen

View Full Filing

View this 10-Q filing on SEC EDGAR